| CAS NO: | 1217651-02-9 |
| 包装 | 价格(元) |
| 500μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1217651-02-9 |
| 别名 | 布林佐胺杂质,AL-4862-d5 |
| Canonical SMILES | O=S(C1=CC([C@@H](NC([2H])([2H])C([2H])([2H])[2H])CN2CCCOC)=C(S1)S2(=O)=O)(N)=O |
| 分子式 | C12H16D5N3O5S3 |
| 分子量 | 388.5 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 半岛bd体育手机客户端 描述 | Brinzolamide-d5 is intended for use as an internal standard for the quantification of brinzolamide by GC- or LC-MS. Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).1 It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension. It also reduces intraocular pressure in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension. |1. DeSantis, L. Preclinical overview of brinzolamide. Surv. Ophthalmol. 44(Suppl. 2), S119-S129 (2000). |
m.cnreagent.com
